Latest News
All Times Eastern
- Pelorus Capital prices first-ever commercial real estate CLO in the cannabis space
- Visa stock price target raised to $255 from $240 at Mizuho
- Mastercard stock price target raised to $435 from $400 at Mizuho
- Airbnb stock price target raised to $145 from $125 at Mizuho
- Barron's Walmart Boosts Stake in Flipkart. Why U.S. Companies Love India.
- Penske Automotive downgraded to underweight from neutral at J.P. Morgan
- Xpeng upgraded to neutral from underweight at J.P. Morgan
- Trip.com upgraded to overweight from neutral at J.P. Morgan
- Sirius XM upgraded to neutral from sell at Seaport Research
- Barron's Apple Grapples With Weak Smartphone Market. This Analyst Says Buy the Stock Anyway.
to be replaced
Apellis Pharmaceuticals Inc.
APLSUS
$
4.44
13.87%
Premarket
$
36.46
Before Hours Volume:
197.19K
| Close | Chg | Chg % |
|---|---|---|
| $32.02 | -0.09 | -0.28% |
Volume: 8.09M
65 Day Avg: 2.99M
27.88
Day Range
32.40
27.88
52 Week Range
94.75
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
APLS Overview
Key Data
- Open $32.28
- Day Range 27.88 - 32.40
- 52 Week Range 27.88 - 94.75
- Market Cap $3.73B
- Shares Outstanding 116.46M
- Public Float 96.09M
- Beta 1.12
- Rev. per Employee $138.05K
- P/E Ratio N/A
- EPS -$6.28
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 9.48M 07/14/23
- % of Float Shorted 9.87%
- Average Volume 2.99M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 15
Full Ratings
Recent News
Biotech and Pharma This Top Pro Invests in Healthcare Trailblazers. 4 of Her Favorite Plays.
Apellis shares gain 16% after FDA accepts new data for drug submission
Shares of Apellis Pharmaceuticals Inc. jumped 16.8% in premarket trading on Friday after the company said the Food and Drug Administration accepted an amendment to its drug-approval submission for a geographic atrophy the...
Biotech and Pharma Apellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for Review
Apellis gets Priority Review designation for geographic atrophy therapy
Shares of Apellis Pharmaceuticals Inc. jumped 24.5% in premarket trading on Tuesday after the company said it received a Priority Review designation from the Food and Drug Administration for its geographic atrophy treatme...
Apellis shares jump 6% after the company announces new data for its geographic atrophy drug
Shares of Apellis Pharmaceuticals Inc. gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data demonstrating that intravitreal pegcetacoplan reduced geographic atrophy lesion growt...
Biotech and Pharma 4 Midsize Biotech Stocks That Have Breakout Potential
Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies
Shares of Apellis Pharmaceuticals Inc. plunged 31.6% toward a 10-month low to pace all premarket losers Friday, after one of the Phase 3 studies of the biopharmaceutical company's eye disease treatment failed to meet its ...
Apellis Pharmaceuticals downgraded to neutral from outperform at Wedbush
Apellis stock price target cut to $57 from $101 at J.P. Morgan
Apellis Pharmaceuticals upgraded to outperform from neutral at Wedbush
Apellis Pharmaceuticals price target raised to $104 from $78, stock rated strong buy
Apellis stock price target raised to $87 from $50 at J.P. Morgan
Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus
EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc
EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc
Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Profarma Distribuidora de Produtos Farmaceuticos S/A Ord | R$457.34M | |
| Joey New York Inc. | ||
| 1pm Industries Inc. | ||
| McKesson Corp. | $54.6B |